MDM2 amplification in malignant Brenner tumors may play a role in progression to malignancy and aid in separation from urothelial and other ovarian carcinomas
- 1 November 2021
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 117, 42-50
Abstract
No abstract availableKeywords
Funding Information
- Cleveland Clinic
This publication has 31 references indexed in Scilit:
- Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinomaLaboratory Investigation, 2020
- Functions of the MDM2 oncoproteinCellular and Molecular Life Sciences, 1999
- Nuclear Export Is Required for Degradation of Endogenous p53 by MDM2 and Human Papillomavirus E6Molecular and Cellular Biology, 1998
- The MDM2 gene amplification databaseNucleic Acids Research, 1998
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumoursBritish Journal of Cancer, 1996
- Amplification of a gene encoding a p53-associated protein in human sarcomasNature, 1992
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992
- Proliferative and malignant brenner tumors of the ovaryCancer, 1972